1. Home
  2. EQ vs DLPN Comparison

EQ vs DLPN Comparison

Compare EQ & DLPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EQ
  • DLPN
  • Stock Information
  • Founded
  • EQ 2017
  • DLPN 1996
  • Country
  • EQ United States
  • DLPN United States
  • Employees
  • EQ N/A
  • DLPN N/A
  • Industry
  • EQ Biotechnology: Pharmaceutical Preparations
  • DLPN Other Consumer Services
  • Sector
  • EQ Health Care
  • DLPN Consumer Discretionary
  • Exchange
  • EQ Nasdaq
  • DLPN Nasdaq
  • Market Cap
  • EQ 13.1M
  • DLPN 12.6M
  • IPO Year
  • EQ 2018
  • DLPN N/A
  • Fundamental
  • Price
  • EQ $0.93
  • DLPN $1.15
  • Analyst Decision
  • EQ Buy
  • DLPN Strong Buy
  • Analyst Count
  • EQ 3
  • DLPN 1
  • Target Price
  • EQ $3.00
  • DLPN $5.00
  • AVG Volume (30 Days)
  • EQ 21.2M
  • DLPN 53.7K
  • Earning Date
  • EQ 08-19-2025
  • DLPN 08-13-2025
  • Dividend Yield
  • EQ N/A
  • DLPN N/A
  • EPS Growth
  • EQ N/A
  • DLPN N/A
  • EPS
  • EQ N/A
  • DLPN N/A
  • Revenue
  • EQ $30,406,000.00
  • DLPN $48,618,803.00
  • Revenue This Year
  • EQ N/A
  • DLPN $6.57
  • Revenue Next Year
  • EQ N/A
  • DLPN $18.10
  • P/E Ratio
  • EQ N/A
  • DLPN N/A
  • Revenue Growth
  • EQ N/A
  • DLPN 0.31
  • 52 Week Low
  • EQ $0.27
  • DLPN $0.75
  • 52 Week High
  • EQ $1.50
  • DLPN $1.70
  • Technical
  • Relative Strength Index (RSI)
  • EQ 71.79
  • DLPN 46.86
  • Support Level
  • EQ $0.46
  • DLPN $1.06
  • Resistance Level
  • EQ $1.25
  • DLPN $1.42
  • Average True Range (ATR)
  • EQ 0.20
  • DLPN 0.10
  • MACD
  • EQ 0.04
  • DLPN -0.01
  • Stochastic Oscillator
  • EQ 57.41
  • DLPN 29.49

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

About DLPN Dolphin Entertainment Inc.

Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.

Share on Social Networks: